Company Overview

Jaguar Health, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing plant-based, sustainably derived gastrointestinal therapies. The company operates within the biopharmaceutical and gastrointestinal (GI) disorders industry, with a strategic emphasis on treating diarrhea and related GI conditions in both human and animal health. Its core revenue driver is the commercialization of its proprietary drug product Mytesi® (crofelemer), which is approved in the United States for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Founded in 2013, Jaguar Health evolved from a focus on animal health into a dual human and animal pharmaceutical platform, leveraging traditional botanical knowledge and modern drug development. The company later reorganized its operations under a holding company structure, integrating human health development through its majority-owned subsidiary Napo Pharmaceuticals, Inc. This evolution reflects Jaguar Health’s strategy to expand crofelemer-based therapies into additional indications and global markets.

Business Operations

Jaguar Health conducts its operations primarily through Napo Pharmaceuticals, Inc., which manages human health drug development and commercialization, and Jaguar Animal Health, which focuses on animal health applications. The company generates revenue mainly from U.S. sales of Mytesi®, while also pursuing clinical development programs targeting orphan and rare diseases such as short bowel syndrome and chemotherapy-induced diarrhea.

Operations include clinical research, regulatory affairs, manufacturing oversight, and commercial distribution, with manufacturing conducted through third-party contract manufacturers. Jaguar Health maintains international development and commercialization partnerships, particularly for ex-U.S. markets, and has entered into regional licensing and distribution agreements to expand the reach of crofelemer-based products without building extensive internal infrastructure.

Strategic Position & Investments

Jaguar Health’s strategic direction centers on expanding the clinical utility of crofelemer, a novel chloride channel modulator, into additional GI indications with high unmet medical need. Growth initiatives include advancing late-stage clinical trials, pursuing orphan drug designations, and expanding access to existing products in international markets through partnerships rather than direct sales forces.

The company has made targeted investments in its pipeline through Napo Pharmaceuticals, Inc., which remains its primary operating subsidiary. Jaguar Health has also pursued collaborations with academic institutions and global health organizations to evaluate crofelemer in infectious and noninfectious diarrhea settings. Its strategic positioning emphasizes sustainability, botanical drug development, and leveraging a single active pharmaceutical ingredient across multiple indications to maximize return on R&D investment.

Geographic Footprint

Jaguar Health is headquartered in San Francisco, California, and its commercial presence is anchored in the United States, where Mytesi® is approved and marketed. The company also maintains an international footprint through licensing and distribution relationships in Latin America, Africa, and parts of Asia, particularly in regions with significant unmet needs in diarrhea-related diseases.

Clinical development activities and market expansion efforts extend beyond North America, reflecting Jaguar Health’s intent to position crofelemer as a globally relevant therapy. While the company does not operate large international offices, its influence is established through regulatory filings, clinical collaborations, and partner-led commercialization strategies across multiple continents.

Leadership & Governance

Jaguar Health was founded with a mission to combine ethnobotanical knowledge with modern pharmaceutical development, a philosophy that continues to influence its leadership and governance. The company’s leadership emphasizes disciplined capital allocation, indication expansion, and partnership-driven growth while navigating the regulatory complexities of botanical drug development.

Key members of the executive leadership include:

• Lisa A. Conte – Founder, President, and Chief Executive Officer
• Russell G. DeLucchi – Chief Financial Officer
• Steve King – Chief of Staff
• Jeffrey F. Riley – General Counsel and Secretary

The leadership team collectively brings experience in pharmaceuticals, finance, regulatory affairs, and global health, guiding Jaguar Health’s long-term strategy of building a differentiated GI-focused pharmaceutical platform based on a single, validated active ingredient.